000136803 001__ 136803
000136803 005__ 20240229105100.0
000136803 0247_ $$2doi$$a10.1007/s11136-018-1866-8
000136803 0247_ $$2pmid$$apmid:29740782
000136803 0247_ $$2ISSN$$a0962-9343
000136803 0247_ $$2ISSN$$a1573-2649
000136803 0247_ $$2altmetric$$aaltmetric:40869146
000136803 037__ $$aDKFZ-2018-01241
000136803 041__ $$aeng
000136803 082__ $$a100
000136803 1001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b0$$eFirst author
000136803 245__ $$aQuality of life, problems, and needs of disease-free breast cancer survivors 5 years after diagnosis.
000136803 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2018
000136803 3367_ $$2DRIVER$$aarticle
000136803 3367_ $$2DataCite$$aOutput Types/Journal article
000136803 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1539690417_27975
000136803 3367_ $$2BibTeX$$aARTICLE
000136803 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136803 3367_ $$00$$2EndNote$$aJournal Article
000136803 520__ $$aAfter cancer treatment, it is desirable to maintain or regain a high quality of life (QoL) and the ability to accomplish everyday tasks well. Therefore, we substantiated the scarce knowledge regarding long-term QoL after breast cancer, burdensome problems, and unmet needs for more support.Disease-free breast cancer survivors (n = 190) who had participated in two randomized controlled exercise trials during primary treatment were followed up to 5 years post-diagnosis. QoL-related functions and symptoms (EORTC QLQ-C30/-BR23), health problems, and support needs were assessed. EORTC-QLQ scores were compared with age-matched normative values from the general population in Germany.QoL-related functions and symptoms in patients during cancer treatment were worse compared to healthy references, but largely improved over time. Yet, cognitive function and sleep were still significantly impaired at 5-year follow-up. Other common long-term problems included sexual issues (45% of survivors), hot flashes (38%), pain (34%), fatigue (24%), and polyneuropathy (21%). Regression analyses indicated fatigue having the strongest impact on global QoL. Support needs were expressed mainly for menopausal disorders (43%), physical performance (39%), sleep problems (38%), arthralgia (37%), cognitive problems (36%), weight problems (32%), and fatigue (31%).While QoL in disease-free breast cancer survivors 5 years post-diagnosis was largely comparable to the general population on average, still many survivors suffered from adverse effects. There appears to be a need for ongoing screening and support regarding fatigue, sleep problems, cognitive problems, arthralgia/pain, menopausal/sexual symptoms, physical performance, and weight problems during and several years following breast cancer therapy.
000136803 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000136803 588__ $$aDataset connected to CrossRef, PubMed,
000136803 7001_ $$0P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aWiskemann, Joachim$$b1
000136803 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b2$$eLast author
000136803 773__ $$0PERI:(DE-600)2008960-0$$a10.1007/s11136-018-1866-8$$gVol. 27, no. 8, p. 2077 - 2086$$n8$$p2077 - 2086$$tQuality of life research$$v27$$x1573-2649$$y2018
000136803 909CO $$ooai:inrepo02.dkfz.de:136803$$pVDB
000136803 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000136803 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aExternal Institute$$b1$$kExtern
000136803 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000136803 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000136803 9141_ $$y2018
000136803 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000136803 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium
000136803 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bQUAL LIFE RES : 2015
000136803 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136803 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136803 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136803 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136803 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136803 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136803 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136803 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136803 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index
000136803 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences
000136803 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000136803 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136803 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000136803 980__ $$ajournal
000136803 980__ $$aVDB
000136803 980__ $$aI:(DE-He78)G210-20160331
000136803 980__ $$aUNRESTRICTED